Golden Analytics | $7,000,000 | (Apr 9, 2026)
HexemBio | $10,400,000 | (Apr 9, 2026)
E2 - Endovascular Engineering | $80,000,000 | (Apr 9, 2026)
Geneos Therapeutics
United States
- Plymouth Meeting, PA
- 13/04/2023
- Series A
- $5,000,000
At Geneos, our passion is to develop personalized therapies to unleash the most powerful force against cancer – your body’s own immune system. Our GT-EPIC Platform is designed to identify relevant neoantigen targets and then design, manufacture, and deliver tumor specific neoantigen-targeted personalized immunotherapies.
- Industry Biotechnology Research
- Website https://www.geneostx.com/
- LinkedIn https://www.linkedin.com/company/geneos-therapeutics/
Related People
Niranjan SardesaiCo Founder
United States -
Blue Bell, Pennsylvania
Executive experienced in developing talent and commercializing technologies for the bio-pharmaceutical and diagnostics marketplace. Strong record in product development and R&D. Particular expertise in:
• Start-up environments and R&D pipeline development
• Corporate financing and M&A
• Organizational development: Hiring and retaining talent
• Valuation of technology and partnering/licensing
• Product development: Vaccines and therapeutics for infectious diseases and oncology
• cGMP environment and regulatory aspects for medical devices and biologics; combination products
• Management of cross-functional and cross-organizational teams
Authored over 120+ peer-reviewed publications/book chapters; presented over 120+ invited lectures/presentations; and inventor on 10+ issued and 70+ patent applications filed/pending US/global
Honored by Pharmavoice Magazine as one of the top 100 most influential and inspirational people from across the Lifesciences and Healthcare Industry (2015)
True Footage | $40,000,000 | (Apr 9, 2026)
Petwealth | $1,700,000 | (Apr 9, 2026)
Pomo | $4,500,000 | (Apr 9, 2026)
Aria Networks, Inc. | $125,000,000 | (Apr 9, 2026)
Trent AI | $13,000,000 | (Apr 9, 2026)
GoSats - The simplest onramp to Digital Assets in India | $5,000,000 | (Apr 9, 2026)
Life Biosciences | $80,000,000 | (Apr 9, 2026)
Noon | $44,000,000 | (Apr 7, 2026)
Miravoice | $6,300,000 | (Apr 7, 2026)